We are a pharmaceutical company with headquarters in Barcelona specialized in research and development activities of high-tech pharmaceutical products for the oncology field, with an specific focus on the treatment of breakthrough pain in cancer patients.
We out-license our highly specialized products to pharmaceutical partners for their commercialization around the world, helping them to increase their R&D capacity and expanding their portfolios that require this specific technology.
Proteus Pharma complies with the highest quality and regulations requirements and its facilities have the latest manufacturing technology, ensuring quality and safety standards worldwide.
Proteus Pharma, as part of the QUBE group, has an ethical code that governs the conduct and activities of executives, employees and government bodies.
To ensure the full and correct effectiveness of the Code of Ethics, an Internal Information System has been implemented . A tool made available to employees and third parties who collaborate with the QUBE group, in order to report any contrary or irregular conduct that occurs within the group or any of its member companies.
Doses: 200 –> 400 –> 600 –> 800 –> 1200 –> 1600 mcg
Reference product: ACTIQ® (CEPHALON/ TEVA)
Unit size: Individual units supplied in blisters of 3/15/30 units
Primary packaging: Each dosage unit is contained in a heat sealed blister package consisting of a paper/foil laminated lid, and a PVC/Aclar thermoformed blister.
Manufacturing site: GMP-plant based in Barcelona
OTFC permits constant fentanyl absorption, so that the plasma peak appears early, but not suddenly (effective and safe).
Better patient compliance and overall efficacy.
OTFC is the only patient self-controlled treatment: optimum safety/efficacy benefit.
Convenience in administration.
Higher safety profile due to the innovative applicator that avoids sobredosification.
There is extensive literature on OTFC in BTP, showing that it is significantly better in terms of SPEED and POTENCY than conventional treatment (including short-acting opiods).
Avda. Baja Navarra 1, 4º E
31002 Pamplona, Spain
proteuspharma@proteuspharma.com